Visual electrophysiological effect of a GABA transaminase blocker

Documenta Ophthalmologica

Volumn 97, Issue 2, 1998, Pages 179-187

  Harding, G F A ^a,b   Robertson, K A ^a   Edson, A S ^a   Barnes, P ^c   Wild, J ^b  

^a Psychology Institute   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

^c Hoechst Marion Roussel   (United Kingdom)

Author keywords

Electro oculogram; Electroretinogram; GABA transaminase; Normal subjects; Vigabatrin

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE INHIBITOR; CARBAMAZEPINE; VIGABATRIN;

ADULT; ANTICONVULSANT THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; ELECTROPHYSIOLOGY; ELECTRORETINOGRAPHY; ENZYME INHIBITION; EVOKED VISUAL RESPONSE; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; OSCILLATORY POTENTIAL;

EID: 0032242974     PISSN: 00124486     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1002045223358     Document Type: Article

References (26)

1. Anon. Sabril Data Sheet. ABPI Data Sheet Compendium of Data Sheets and Summaries of Product Characteristics (1998-1999). Association of the British Pharmaceutical Industry.
2. Arezzo JC, Schroeder CE. Litwak MS, Steward DL. Effects of vigabatrin on evoked potentials in dogs. Br J Clin Pharmacol 1989; 27: 53S-60S.
3. Ben-Menachem E, Persson LI, Schechter PJ et al. The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients. Br J Clin Pharmacol 1989; 27: 79S-85S
4. Butler WH, Ford GP, Newberne JW. A study of the effects of vigabatrin on the central nervous system and retina of Sprague Dawley and Lister-Hooded rats. Toxicol Pathol 1987; 15: 143-8.
5. Dawson W.W., Trick G.L., Litzkow CA. Improved electrode for electroretinography. Invest. Ophthalmol. Vis., Sci 1979; 18: 988-91.
6. Duckett T. Brigell M, Ruckh S. Electroretinographic changes are not associated with loss of visual function in pediatric epileptic patients following treatment with vigabatrin. Invest. Ophthalmol. Vis. Sci 1998; 39(4): S973, May 10-15.
7. Eke T, Talbot J.F., Lawden M.C. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997; 314: 180-81.
8. Gibson JP, Yarrington JT, Loudy DE, Gerbig CG et al. Chronic toxicity studies with vigabatrin: a GABA-transaminase inhibitor. Toxicol Pathol 1990; 18: 225-38.
9. Graham D. Neuropathology of vigabatrin. Br J Clin Pharmacol 1989; 27: 43S-45S.
10. Gram L, Klosterskov P, Dam M. Gamma-vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Ann Neurol 1985; 17: 262-6.
11. Haegele KD, Schecter PJ. Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active 5-enantiomer. Clin Pharmacol Ther 1986; 40: 581-86.
12. Harding G.F.A., Jones L.A., Tipper V.J., Betts T.A., Mumford J.P. Electroretinogram, pattern electroretinogram & visual evoked potential assessment in patients receiving vigabatrin. Epilepsia 1995; 36: (3), 30.
13. Harding G.F.A. Severe persistent visual field constriction associated with vigabatrin. Four possible explanations exist. BMJ 1997; 7, 314, (7095): 1694.
14. Harding G.F.A., Wild J.M, Robertson K.A., Edson A., Barber C., Lawden M., Betts T. Electrooculography, ERGs, multifocal ERGs and VEPs in epileptic patients showing visual field disorders. Electroenceph. Clin. Neurophysiol 1997; 103, (1): 96.
15. Harding G.F.A., Wild J.M, Robertson K.A., Lawden M., Betts T.A., Barber CM., Barnes P.M.F. EOGs, ERGs, VEPs and Multifocal ERGs in epileptic patients showing visual field constriction. EEG Journal 1999; (in press)
16. Kälväinen R, Aikiä M, Mervaala E at al. Vigabatrin versus carbamazepine monotherapy in newly diagnosed patients with epilepsy. Archives of Neurology 1995; 52: 989-96.
17. Krauss G.L., Johnson M.A., Miller N.R. Vigabatrin-associated retinal cone system dysfunction. Electroretinogram and ophthalmic findings. Neurology 1998; 50: (3), 614-8.
18. Lawden M.C., Eke T., Degg C., Harding G.F.A., Wild J.M. Visual field defects associated with vigabatrin therapy. Journal of Neurology, Neurosurgery and Psychiatry. (In Press).
19. Marmor ME, Zrenner E. Standard for clinical electrooculography. Documenta Ophthalmologica 1993; 85:115-24.
20. Marmor ME, Zrenner E. Standard for clinical electroretinography. Documenta Ophthalmologica 1994; 89: 199-210.
21. Mumford J.P. Tolerability and Safety Profile of Vigabatrin. In: Reviews in Contemporary Pharmacotherapy-Vigabatrin 1995; 6, (9): 477-83.
22. Neal MJ, Cunningham JR, Shah MA, Yazulla S. Immunocytochemical evidence that vigabatrin in rats cause GABA accumulation in glial cells of the retina. Neurosci. Lett. 1988; 98, 29-32.
23. Patsalos PN, Duncan JS. The pharmacology and pharmacokinetics of vigabatrin.In: Reviews in Contemporary Pharmacotherapy - Vigabatrin 1995; 6, (9): 447-56.
24. Pow.. , Rogers .. GABA transamination regulates neuronal glutamate content in the retina, Neuroreport 1996; 7, 2683-6.
25. Schecter PJ. Clinical pharmacology of vigabatrin. Br J Clin Pharmacol 1989; 27: 19S-22S.
26. Vles JSH, van den Heyden AMGH, Ghijs A et al. Vigabatrin in the treatment of infantile spasms. Neuropediatrics 1993; 24: 230-1.